07 Jun 2025
// PRESS RELEASE
https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html
17 Jan 2025
// PRESS RELEASE
https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html
03 Oct 2024
// BUSINESSWIRE
30 Jul 2024
// PRESS RELEASE
https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html
16 Jun 2024
// BUSINESSWIRE
21 May 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-aims-deliver-80-billion-total-revenue-by-2030-2024-05-21/